IFNG overexpression
|
Melanoma
|
IFNG overexpression
|
Melanoma
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
IFNG overexpression
|
SCCHN
|
IFNG overexpression
|
SCCHN
|
pembrolizumab Sensitive: C3 – Early Trials
|
pembrolizumab Sensitive: C3 – Early Trials
|